{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:27:08Z","timestamp":1790400428811,"version":"4.1.0"},"reference-count":88,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["EC GNT1159536"],"award-info":[{"award-number":["EC GNT1159536"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["RW GNT2009767"],"award-info":[{"award-number":["RW GNT2009767"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"Abstract<\/jats:title>\n \n STUDY QUESTION<\/jats:title>\n Which assited reproductive technology (ART) interventions in high-income countries are cost-effective and which are not?<\/jats:p>\n <\/jats:sec>\n \n SUMMARY ANSWER<\/jats:title>\n Among all ART interventions assessed in economic evaluations, most high-cost interventions, including preimplantation genetic testing for aneuploidy (PGT-A) for a general population and ICSI for unexplained infertility, are unlikely to be cost-effective owing to minimal or no increase in effectiveness.<\/jats:p>\n <\/jats:sec>\n \n WHAT IS KNOWN ALREADY<\/jats:title>\n Approaches to reduce costs in order to increase access have been identified as a research priority for future infertility research. There has been an increasing number of ART interventions implemented in routine clinical practice globally, before robust assessments of evidence on economic evaluations. The extent of clinical effectiveness of some studied comparisons has been evaluated in high-quality research, allowing more informative decision making around cost-effectiveness.<\/jats:p>\n <\/jats:sec>\n \n STUDY DESIGN, SIZE, DURATION<\/jats:title>\n We performed a systematic review and searched seven databases (MEDLINE, PUBMED, EMBASE, COCHRANE, ECONLIT, SCOPUS, and CINAHL) for studies examining ART interventions for infertility together with an economic evaluation component (cost-effectiveness, cost-benefit, cost-utility, or cost-minimization assessment), in high-income countries, published since January 2011. The last search was 22 June 2022.<\/jats:p>\n <\/jats:sec>\n \n PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n Two independent reviewers assessed publications and included those fulfilling the eligibility criteria. Studies were examined to assess the cost-effectiveness of the studied intervention, as well as the reporting quality of the study. The chosen outcome measure and payer perspective were also noted. Completeness of reporting was assessed against the Consolidated Health Economic Evaluation Reporting Standard. Results are presented and summarized based on the intervention studied.<\/jats:p>\n <\/jats:sec>\n \n MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n The review included 40 studies which were conducted in 11 high-income countries. Most studies (n\u2009=\u200934) included a cost-effectiveness analysis. ART interventions included medication or strategies for controlled ovarian stimulation (n\u2009=\u200915), IVF (n\u2009=\u20099), PGT-A (n\u2009=\u20097), single embryo transfer (n\u2009=\u20095), ICSI (n\u2009=\u20093), and freeze-all embryo transfer (n\u2009=\u20091). Live birth was the mostly commonly reported primary outcome (n\u2009=\u200927), and quality-adjusted life years was reported in three studies. The health funder perspective was used in 85% (n\u2009=\u200934) of studies. None of the included studies measured patient preference for treatment. It remains uncertain whether PGT-A improves pregnancy rates compared to IVF cycles managed without PGT-A, and therefore cost-effectiveness could not be demonstrated for this intervention. Similarly, ICSI in non-male factor infertility appears not to be clinically effective compared to standard fertilization in an IVF cycle and is therefore not cost-effective. Interventions such as use of biosimilars or HMG for ovarian stimulation are cheaper but compromise clinical effectiveness.<\/jats:p>\n <\/jats:sec>\n \n LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n Lack of both preference-based and standardized outcomes limits the comparability of results across studies. The selection of efficacy evidence offered for some interventions for economic evaluations is not always based on high-quality randomized trials and systematic reviews. In addition, there is insufficient knowledge of the willingness to pay thresholds of individuals and state funders for treatment of infertility. There is variable quality of reporting scores, which might increase uncertainty around the cost-effectiveness results.<\/jats:p>\n <\/jats:sec>\n \n WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n Investment in strategies to help infertile people who utilize ART is justifiable at both personal and population levels. This systematic review may assist ART funders decide how to best invest to maximize the likelihood of delivery of a healthy child.<\/jats:p>\n <\/jats:sec>\n \n STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n There was no funding for this study. E.C. and R.W. receive salary support from the National Health and Medical Research Council (NHMRC) through their fellowship scheme (EC GNT1159536, RW 2021\/GNT2009767). M.D.-T. reports consulting fees from King Fahad Medical School. All other authors have no competing interests to declare.<\/jats:p>\n <\/jats:sec>\n \n REGISTRATION NUMBER<\/jats:title>\n Prospero CRD42021261537.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/humrep\/deae039","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T01:21:30Z","timestamp":1709601690000},"page":"981-991","source":"Crossref","is-referenced-by-count":20,"title":["Economic evaluations of assisted reproductive technologies in high-income countries: a systematic review"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3366-4204","authenticated-orcid":false,"given":"Emily","family":"Olive","sequence":"first","affiliation":[{"name":"Discipline of Obstetrics, Gynaecology and Neonatology, Faculty of Medicine and Health, University of Sydney , Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bull","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Queensland , Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Gordon","sequence":"additional","affiliation":[{"name":"Discipline of Obstetrics, Gynaecology and Neonatology, Faculty of Medicine and Health, University of Sydney , Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Davies-Tuck","sequence":"additional","affiliation":[{"name":"The Ritchie Centre, Hudson Institute of Medical Research , Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-8134","authenticated-orcid":false,"given":"Rui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Monash University , Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Callander","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Technology Sydney , Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"2024050205544451900_deae039-B1","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/humrep\/deab207","article-title":"Assessing couples\u2019 preferences for fresh or frozen embryo transfer: a discrete choice experiment","volume":"36","author":"Abdulrahim","year":"2021","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/2050312120931988","article-title":"Cost-effectiveness of assisted reproductive technologies in Saudi Arabia: comparing in vitro fertilization with intrauterine insemination","volume":"8","author":"Almaslami","year":"2020","journal-title":"SAGE Open Med"},{"key":"2024050205544451900_deae039-B3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.fertnstert.2020.05.032","article-title":"Intracytoplasmic sperm injection (ICSI) for non-male factor indications: a committee opinion","volume":"114","author":"American Society for Reproductive Medicine","year":"2020","journal-title":"Fertil Steril"},{"key":"2024050205544451900_deae039-B4","doi-asserted-by":"crossref","first-page":"e034566","DOI":"10.1136\/bmjopen-2019-034566","article-title":"Observational retrospective study of UK national success, risks and costs for 319,105 IVF\/ICSI and 30,669 IUI treatment cycles","volume":"10","author":"Bahadur","year":"2020","journal-title":"BMJ Open"},{"key":"2024050205544451900_deae039-B5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.rbms.2018.01.001","article-title":"Comparative economic study of the use of corifollitropin alfa and daily rFSH for controlled ovarian stimulation in older patients: cost-minimization analysis based on the PURSUE study","volume":"5","author":"Barrenetxea","year":"2018","journal-title":"Reprod Biomed Soc Online"},{"key":"2024050205544451900_deae039-B6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40258-017-0361-7","article-title":"Cost-effectiveness analysis of the gonadotropin treatments HP-hMG and rFSH for assisted reproductive technology in France: a Markov model analysis","volume":"16","author":"Barriere","year":"2018","journal-title":"Appl Health Econ Health Policy"},{"key":"2024050205544451900_deae039-B7","doi-asserted-by":"crossref","first-page":"e20171726","DOI":"10.1542\/peds.2017-1726","article-title":"Neonatal morbidity at term, early child development, and school performance: a population study","volume":"141","author":"Bentley","year":"2018","journal-title":"Pediatrics"},{"key":"2024050205544451900_deae039-B8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jama.2014.17985","article-title":"Trends in use of and reproductive outcomes associated with intracytoplasmic sperm injection","volume":"313","author":"Boulet","year":"2015","journal-title":"Jama"},{"key":"2024050205544451900_deae039-B9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.fertnstert.2017.01.017","article-title":"Obesity and female infertility: potential mediators of obesity\u2019s impact","volume":"107","author":"Broughton","year":"2017","journal-title":"Fertil Steril"},{"key":"2024050205544451900_deae039-B10","first-page":"89","article-title":"Prognosis and cost-effectiveness of IVF in poor responders according to the Bologna criteria","volume":"70","author":"Busnelli","year":"2018","journal-title":"Minerva Ginecol"},{"key":"2024050205544451900_deae039-B11","doi-asserted-by":"crossref","first-page":"hoz044","DOI":"10.1093\/hropen\/hoz044","article-title":"Survey on ART and IUI: legislation, regulation, funding and registries in European countries: the European IVF-Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE)","volume":"2020","author":"Calhaz-Jorge","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2024050205544451900_deae039-B12","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1080\/14767058.2020.1771690","article-title":"IVF\/ICSI treatment and the risk of iatrogenic preterm birth in singleton pregnancies: systematic review and meta-analysis of cohort studies","volume":"35","author":"Cavoretto","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2024050205544451900_deae039-B13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/humupd\/dmaa047","article-title":"IVF and other ART in low- and middle-income countries: a systematic landscape analysis","volume":"27","author":"Chiware","year":"2021","journal-title":"Hum Reprod Update"},{"key":"2024050205544451900_deae039-B14","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/humrep\/deaa129","article-title":"Age-related natural fertility outcomes in women over 35 years: a systematic review and individual participant data meta-analysis","volume":"35","author":"Chua","year":"2020","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B15","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s10815-017-1001-8","article-title":"Cost-effectiveness of preimplantation genetic screening for women older than 37 undergoing in vitro fertilization","volume":"34","author":"Collins","year":"2017","journal-title":"J Assist Reprod Genet"},{"key":"2024050205544451900_deae039-B16","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/S0140-6736(21)00535-3","article-title":"Intracytoplasmic sperm injection versus conventional in-vitro fertilisation in couples with infertility in whom the male partner has normal total sperm count and motility: an open-label, randomised controlled trial","volume":"397","author":"Dang","year":"2021","journal-title":"Lancet"},{"key":"2024050205544451900_deae039-B17","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/humrep\/dew123","article-title":"Prevalence of infertility and help seeking among 15 000 women and men","volume":"31","author":"Datta","year":"2016","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B18","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/humrep\/dey242","article-title":"ART in Europe, 2014: results generated from European registries by ESHRE: the European IVF-Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE)","volume":"33","author":"de Geyter","year":"2018","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B19","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1093\/humrep\/deaa250","article-title":"20 years of the European IVF-monitoring Consortium registry: what have we learned? A comparison with registries from two other regions","volume":"35","author":"de Geyter","year":"2020","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B20","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.rbmo.2021.09.002","article-title":"Barriers and factors associated with significant delays to initial consultation and treatment for infertile patients and partners of infertile patients","volume":"43","author":"Domar","year":"2021","journal-title":"Reprod Biomed Online"},{"key":"2024050205544451900_deae039-B21","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.fertnstert.2020.11.014","article-title":"Top 10 priorities for future infertility research: an international consensus development study","volume":"115","author":"Duffy","year":"2021","journal-title":"Fertil Steril"},{"key":"2024050205544451900_deae039-B22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.fertnstert.2020.11.012","article-title":"Developing a core outcome set for future infertility research: an international consensus development study","volume":"115","author":"Duffy","year":"2021","journal-title":"Fertil Steril"},{"key":"2024050205544451900_deae039-B23","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/humrep\/dex315","article-title":"Poor recovery of households from out-of-pocket payment for assisted reproductive technology","volume":"32","author":"Dyer","year":"2017","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B24","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/humrep\/dex018","article-title":"Cost-effectiveness of \u2018immediate IVF\u2019 versus \u2018delayed IVF\u2019: a prospective study","volume":"32","author":"Eijkemans","year":"2017","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B25","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1093\/humrep\/dev163","article-title":"Economic aspects of infertility care: a challenge for researchers and clinicians","volume":"30","author":"ESHRE Capri Workshop Group","year":"2015","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B26","doi-asserted-by":"crossref","first-page":"hoab026","DOI":"10.1093\/hropen\/hoab026","article-title":"ART in Europe 2017: results generated from European registries by ESHRE","volume":"2021","author":"European IVF Monitoring Consortium for the European Society of Human Reproduction, Embryology","year":"2021","journal-title":"Hum Reprod Open"},{"key":"2024050205544451900_deae039-B27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.rbmo.2018.12.044","article-title":"Evaluation of the cost-effectiveness of ovulation suppression with progestins compared with GnRH analogs in assisted reproduction cycles","volume":"38","author":"Evans","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"2024050205544451900_deae039-B28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/CEOR.S31972","article-title":"Economic evaluation of alternative assisted reproduction techniques in management of infertility in Greece","volume":"4","author":"Fragoulakis","year":"2012","journal-title":"Clinicoecon Outcomes Res"},{"key":"2024050205544451900_deae039-B29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40258-016-0259-9","article-title":"Economic evaluation of three frequently used gonadotrophins in assisted reproduction techniques in the management of infertility in the Netherlands","volume":"14","author":"Fragoulakis","year":"2016","journal-title":"Appl Health Econ Health Policy"},{"key":"2024050205544451900_deae039-B30","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1093\/humrep\/17.12.3090","article-title":"Economic implications of assisted reproductive techniques: a systematic review","volume":"17","author":"Garceau","year":"2002","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B31","doi-asserted-by":"crossref","first-page":"A519","DOI":"10.1016\/j.jval.2017.08.686","article-title":"A cost-effectiveness modeling evaluation comparing originator follitropin alfa to a biosimilar for the treatment of infertility in Germany, Italy and Spain","volume":"20","author":"Gizzo","year":"2017","journal-title":"Value Health"},{"key":"2024050205544451900_deae039-B32","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1080\/13696998.2018.1511567","article-title":"A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain","volume":"21","author":"Gizzo","year":"2018","journal-title":"J Med Econ"},{"key":"2024050205544451900_deae039-B33","doi-asserted-by":"crossref","first-page":"hoz017","DOI":"10.1093\/hropen\/hoz017","article-title":"Worldwide decline of IVF birth rates and its probable causes","volume":"2019","author":"Gleicher","year":"2019","journal-title":"Hum Reprod Open"},{"key":"2024050205544451900_deae039-B34","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molmed.2020.11.009","article-title":"Preimplantation genetic testing for aneuploidy\u2014a castle built on sand","volume":"27","author":"Gleicher","year":"2021","journal-title":"Trends Mol Med"},{"key":"2024050205544451900_deae039-B35","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1093\/humrep\/det386","article-title":"Modified natural cycle versus controlled ovarian hyperstimulation IVF: a cost-effectiveness evaluation of three simulated treatment scenarios","volume":"28","author":"Groen","year":"2013","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B36","first-page":"1","article-title":"A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective","volume":"22","author":"Grynberg","year":"2018","journal-title":"J Med Econ"},{"key":"2024050205544451900_deae039-B37","volume-title":"Assisted Reproductive Technology in Australia and New Zealand 2014","author":"Harris","year":"2016"},{"key":"2024050205544451900_deae039-B38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.fertnstert.2014.11.032","article-title":"Economic evaluation of elective single-embryo transfer with subsequent single frozen embryo transfer in an in vitro fertilization\/intracytoplasmic sperm injection program","volume":"103","author":"Hernandez Torres","year":"2015","journal-title":"Fertil Steril"},{"key":"2024050205544451900_deae039-B39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"2024050205544451900_deae039-B40","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/GRH.0000000000000029","article-title":"International Federation of Fertility Societies\u2019 Surveillance (IFFS) 2019: global trends in reproductive policy and practice, 8th edition","volume":"4","author":"International Federation of Fertility Societies\u2019 Surveillance (IFFS)","year":"2019","journal-title":"Glob Reprod Health"},{"key":"2024050205544451900_deae039-B41","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1097\/GRH.0000000000000058","article-title":"International Federation of Fertility Societies\u2019 Surveillance (IFFS) 2022: global trends in reproductive policy and practice, 9th edition","volume":"7","author":"International Federation of Fertility Societies\u2019 Surveillance (IFFS)","year":"2022","journal-title":"Glob Reprod Health"},{"key":"2024050205544451900_deae039-B42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.fertnstert.2020.09.155","article-title":"Fertility-a human right worthy of mandated insurance coverage: the evolution, limitations, and future of access to care","volume":"115","author":"Kawwass","year":"2021","journal-title":"Fertil Steril"},{"key":"2024050205544451900_deae039-B43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40738-020-00076-1","article-title":"The prevalence of anxiety symptoms in infertile women: a systematic review and meta-analysis","volume":"6","author":"Kiani","year":"2020","journal-title":"Fertil Res Pract"},{"key":"2024050205544451900_deae039-B44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12958-016-0225-2","article-title":"Systematic review of worldwide trends in assisted reproductive technology 2004-2013","volume":"15","author":"Kushnir","year":"2017","journal-title":"Reprod Biol Endocrinol"},{"key":"2024050205544451900_deae039-B45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/ajo.12988","article-title":"A cost-effectiveness analysis of preimplantation genetic testing for aneuploidy (PGT-A) for up to three complete assisted reproductive technology cycles in women of advanced maternal age","volume":"59","author":"Lee","year":"2019","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"2024050205544451900_deae039-B46","doi-asserted-by":"crossref","first-page":"55.e1","DOI":"10.1016\/j.ajog.2021.01.021","article-title":"The cost-effectiveness of preimplantation genetic testing for aneuploidy in the United States: an analysis of cost and birth outcomes from 158,665 in vitro fertilization cycles","volume":"225","author":"Lee","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"2024050205544451900_deae039-B47","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/humrep\/deab098","article-title":"How common is add-on use and how do patients decide whether to use them? A national survey of IVF patients","volume":"36","author":"Lensen","year":"2021","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12958-018-0386-2","article-title":"Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with recombinant FSH plus recombinant LH vs. human menopausal gonadotropin for women undergoing IVF","volume":"16","author":"Mennini","year":"2018","journal-title":"Reprod Biol Endocrinol"},{"key":"2024050205544451900_deae039-B49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/humrep\/des347","article-title":"Infertility and the risk of adverse pregnancy outcomes: a systematic review and meta-analysis","volume":"28","author":"Messerlian","year":"2012","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B50","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.fertnstert.2011.06.072","article-title":"Cost effectiveness of ovarian reserve testing in in vitro fertilization: a Markov decision-analytic model","volume":"96","author":"Moolenaar","year":"2011","journal-title":"Fertil Steril"},{"key":"2024050205544451900_deae039-B51","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.rbmo.2015.02.006","article-title":"Cost-effectiveness of assisted conception for male subfertility","volume":"30","author":"Moolenaar","year":"2015","journal-title":"Reprod Biomed Online"},{"key":"2024050205544451900_deae039-B52","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.fertnstert.2018.06.021","article-title":"Preimplantation genetic testing for aneuploidy is cost-effective, shortens treatment time, and reduces the risk of failed embryo transfer and clinical miscarriage","volume":"110","author":"Neal","year":"2018","journal-title":"Fertil Steril"},{"key":"2024050205544451900_deae039-B53","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1055\/a-1079-5283","article-title":"An economic analysis of aneuploidy screening of oocytes in assisted reproduction in Germany","volume":"80","author":"Neumann","year":"2020","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"2024050205544451900_deae039-B54","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/1471-0528.16089","article-title":"An economic analysis of preimplantation genetic testing for aneuploidy by polar body biopsy in advanced maternal age","volume":"127","author":"Neumann","year":"2020","journal-title":"BJOG"},{"key":"2024050205544451900_deae039-B55","volume-title":"Assisted Reproductive Technology in Australia and New Zealand 2019","author":"Newman","year":"2021"},{"key":"2024050205544451900_deae039-B56","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10815-018-01399-1","article-title":"Single best euploid versus single best unknown-ploidy blastocyst frozen embryo transfers: a randomized controlled trial","volume":"36","author":"Ozgur","year":"2019","journal-title":"J Assist Reprod Genet"},{"key":"2024050205544451900_deae039-B57","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"2024050205544451900_deae039-B58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.rbmo.2016.09.008","article-title":"A direct healthcare cost analysis of the cryopreserved versus fresh transfer policy at the blastocyst stage","volume":"34","author":"Papaleo","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2024050205544451900_deae039-B59","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.fertnstert.2021.06.013","article-title":"Innovations in infertility: a comprehensive analysis of the ClinicalTrials.gov database","volume":"116","author":"Peipert","year":"2021","journal-title":"Fertil Steril"},{"key":"2024050205544451900_deae039-B60","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.rbmo.2018.08.024","article-title":"Cost-effectiveness modelling of IVF in couples with unexplained infertility","volume":"37","author":"Pham","year":"2018","journal-title":"Reprod Biomed Online"},{"key":"2024050205544451900_deae039-B61","first-page":"257","article-title":"Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer-High Responder (MEGASET-HR) trial","volume":"1","author":"Robins","year":"2020","journal-title":"F S Rep"},{"key":"2024050205544451900_deae039-B62","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1471-0528.2011.02966.x","article-title":"Minimising twins in in vitro fertilisation: a modelling study assessing the costs, consequences and cost-utility of elective single versus double embryo transfer over a 20-year time horizon","volume":"118","author":"Scotland","year":"2011","journal-title":"BJOG"},{"key":"2024050205544451900_deae039-B63","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3109\/09513590.2011.579655","article-title":"Clinical and economic analysis of rescue intracytoplasmic sperm injection cycles","volume":"27","author":"Shalom-Paz","year":"2011","journal-title":"Gynecol Endocrinol"},{"key":"2024050205544451900_deae039-B64","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13643-020-01536-x","article-title":"Challenges in synthesising cost-effectiveness estimates","volume":"9","author":"Shields","year":"2020","journal-title":"Syst Rev"},{"key":"2024050205544451900_deae039-B65","doi-asserted-by":"crossref","first-page":"e1700","DOI":"10.1093\/milmed\/usaa119","article-title":"Single embryo transfer versus double embryo transfer: a cost-effectiveness analysis in a non-IVF insurance mandated system","volume":"185","author":"Sitler","year":"2020","journal-title":"Mil Med"},{"key":"2024050205544451900_deae039-B66","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.fertnstert.2019.01.025","article-title":"Cost-effectiveness of preimplantation genetic testing for aneuploidies","volume":"111","author":"Somigliana","year":"2019","journal-title":"Fertil Steril"},{"key":"2024050205544451900_deae039-B67","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/humrep\/dew066","article-title":"Age-related infertility and unexplained infertility: an intricate clinical dilemma","volume":"31","author":"Somigliana","year":"2016","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B68","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/humrep\/dez006","article-title":"Patients\u2019 attitudes and preferences towards a freeze-all strategy in ART treatment","volume":"34","author":"Stormlund","year":"2019","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B69","volume-title":"2021 Intergenerational Report","author":"The Commonwealth of Australia","year":"2021"},{"key":"2024050205544451900_deae039-B70","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/humrep\/deaa034","article-title":"The status of preimplantation genetic testing in the UK and USA","volume":"35","author":"Theobald","year":"2020","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B71","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.fertnstert.2019.07.1323","article-title":"Assisted reproductive technology use in the United States: a population assessment","volume":"112","author":"Tierney","year":"2019","journal-title":"Fertil Steril"},{"key":"2024050205544451900_deae039-B72","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1093\/humrep\/dev193","article-title":"Is IVF-served two different ways-more cost-effective than IUI with controlled ovarian hyperstimulation?","volume":"30","author":"Tjon-Kon-Fat","year":"2015","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B73","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.fertnstert.2016.05.026","article-title":"Society for assisted reproductive technology and assisted reproductive technology in the United States: a 2016 update","volume":"106","author":"Toner","year":"2016","journal-title":"Fertil Steril"},{"key":"2024050205544451900_deae039-B74","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/S1701-2163(16)30080-9","article-title":"Assisted reproductive technologies in Alberta: an economic analysis to inform policy decision-making","volume":"37","author":"Vaidya","year":"2015","journal-title":"J Obstet Gynaecol Can"},{"key":"2024050205544451900_deae039-B75","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/humrep\/deaa158","article-title":"Cost-effectiveness of medically assisted reproduction or expectant management for unexplained subfertility: when to start treatment?","volume":"35","author":"van Eekelen","year":"2020","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B76","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1093\/humrep\/dew229","article-title":"Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF","volume":"31","author":"van Heesch","year":"2016","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B77","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejogrb.2017.04.031","article-title":"Cost-effectiveness of single versus double embryo transfer in IVF in relation to female age","volume":"214","author":"van Loendersloot","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2024050205544451900_deae039-B78","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.rbmo.2013.10.021","article-title":"IVF with planned single-embryo transfer versus IUI with ovarian stimulation in couples with unexplained subfertility: an economic analysis","volume":"28","author":"van Rumste","year":"2014","journal-title":"Reprod Biomed Online"},{"key":"2024050205544451900_deae039-B79","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/humrep\/dex321","article-title":"Individualized FSH dosing based on ovarian reserve testing in women starting IVF\/ICSI: a multicentre trial and cost-effectiveness analysis","volume":"32","author":"van Tilborg","year":"2017","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B80","volume-title":"Covidence Systematic Review Software","author":"Veritas Health Innovation.","year":"2021"},{"key":"2024050205544451900_deae039-B81","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.fertnstert.2013.06.035","article-title":"Management of the first in vitro fertilization cycle for unexplained infertility: a cost-effectiveness analysis of split in vitro fertilization-intracytoplasmic sperm injection","volume":"100","author":"Vitek","year":"2013","journal-title":"Fertil Steril"},{"key":"2024050205544451900_deae039-B82","volume-title":"World Bank Country and Lending Groups","author":"World Bank","year":"2021"},{"key":"2024050205544451900_deae039-B83","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2147\/IJWH.S193048","article-title":"A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany","volume":"11","author":"Xue","year":"2019","journal-title":"Int J Womens Health"},{"key":"2024050205544451900_deae039-B84","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2103613","article-title":"Live birth with or without preimplantation genetic testing for aneuploidy","volume":"385","author":"Yan","year":"2021","journal-title":"N Engl J Med"},{"key":"2024050205544451900_deae039-B85","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/humrep\/der182","article-title":"Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF","volume":"26","author":"Yates","year":"2011","journal-title":"Hum Reprod"},{"key":"2024050205544451900_deae039-B86","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/biolre\/ioz084","article-title":"Genetics of human female infertility","volume":"101","author":"Yatsenko","year":"2019","journal-title":"Biol Reprod"},{"key":"2024050205544451900_deae039-B87","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.fertnstert.2014.05.015","article-title":"Cost-effectiveness analysis comparing continuation of assisted reproductive technology with conversion to intrauterine insemination in patients with low follicle numbers","volume":"102","author":"Yu","year":"2014","journal-title":"Fertil Steril"},{"key":"2024050205544451900_deae039-B88","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMra1810764","article-title":"Endometriosis","volume":"382","author":"Zondervan","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/39\/5\/981\/57365675\/deae039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/39\/5\/981\/57365675\/deae039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T05:59:02Z","timestamp":1714629542000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/39\/5\/981\/7618943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":88,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3,4]]},"published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deae039","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2024,3,4]]}}}